ATE94070T1 - Faktor xiii zur vorbeugung von intraventrikulaeren blutungen. - Google Patents

Faktor xiii zur vorbeugung von intraventrikulaeren blutungen.

Info

Publication number
ATE94070T1
ATE94070T1 AT89102471T AT89102471T ATE94070T1 AT E94070 T1 ATE94070 T1 AT E94070T1 AT 89102471 T AT89102471 T AT 89102471T AT 89102471 T AT89102471 T AT 89102471T AT E94070 T1 ATE94070 T1 AT E94070T1
Authority
AT
Austria
Prior art keywords
factor xiii
prevent
bleeding
intraventricular bleeding
prevent intraventricular
Prior art date
Application number
AT89102471T
Other languages
German (de)
English (en)
Inventor
Akira Shirahata
Minoru Uchida
Satoshi Tanaka
Kenichiro Tsumura
Original Assignee
Hoechst Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan filed Critical Hoechst Japan
Application granted granted Critical
Publication of ATE94070T1 publication Critical patent/ATE94070T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT89102471T 1988-02-24 1989-02-14 Faktor xiii zur vorbeugung von intraventrikulaeren blutungen. ATE94070T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63039646A JPH01216939A (ja) 1988-02-24 1988-02-24 末熟児頭蓋内出血阻止剤
EP89102471A EP0330049B1 (en) 1988-02-24 1989-02-14 Factor xiii for the prevention of intraventricular hemorrhage

Publications (1)

Publication Number Publication Date
ATE94070T1 true ATE94070T1 (de) 1993-09-15

Family

ID=12558846

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89102471T ATE94070T1 (de) 1988-02-24 1989-02-14 Faktor xiii zur vorbeugung von intraventrikulaeren blutungen.

Country Status (12)

Country Link
US (1) US5114916A (enExample)
EP (1) EP0330049B1 (enExample)
JP (1) JPH01216939A (enExample)
KR (1) KR0137476B1 (enExample)
AT (1) ATE94070T1 (enExample)
AU (1) AU613154B2 (enExample)
CA (1) CA1332352C (enExample)
DE (1) DE68908913T2 (enExample)
DK (1) DK174978B1 (enExample)
ES (1) ES2059588T3 (enExample)
IE (1) IE63656B1 (enExample)
PT (1) PT89802B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612456A (en) * 1988-11-14 1997-03-18 Zymogenetics, Inc. Factor XIII compositions
JPH07502734A (ja) * 1991-12-31 1995-03-23 ザイモジェネティクス，インコーポレイティド 血液損失を減少する方法および組成物
WO1993020837A1 (fr) * 1992-04-21 1993-10-28 Ajinomoto Co., Inc. Remede contre les plaies
DE69326349T2 (de) * 1992-11-12 2000-03-02 Mayberg, Marc R. Verwendung von lokal appliziertem faktor xiii zur verhinderung von blutungen
JPH07328108A (ja) * 1994-06-10 1995-12-19 Ajinomoto Co Inc 生体組織接着剤及び血液凝固剤
PT1588716E (pt) 1998-08-06 2011-05-25 Mountain View Pharmaceuticals Conjugados de peg-urato oxidase e sua utiliza??o
JP2008510476A (ja) * 2004-08-27 2008-04-10 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 生物学的材料からのｘｉｉｉ因子ポリペプチドの精製
JP5086093B2 (ja) * 2004-11-23 2012-11-28 ジモジェネティクス、インコーポレイテッド 組換え型ヒトｘｉｉｉ因子の精製
LT3321359T (lt) 2005-04-11 2021-05-10 Horizon Pharma Rheumatology Llc Urato oksidazės variantinės formos ir jų panaudojimas
TWI418564B (zh) * 2005-04-11 2013-12-11 Savient Pharmaceuticals Inc 利用陽離子界面活性劑之蛋白質純化
JP5033177B2 (ja) * 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク． 陽イオン界面活性剤によるタンパク質の精製
PL398781A1 (pl) 2009-06-25 2012-11-19 Savient Pharmaceuticals, Inc. Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
DE2063070C3 (de) * 1970-12-22 1975-07-24 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Arzneimittels mit fibrinstabilisierender Wirkung
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
DE3751269T2 (de) * 1986-09-19 1995-09-14 Univ Washington Expression des biologisch aktiven Faktors XIII.

Also Published As

Publication number Publication date
PT89802A (pt) 1989-10-04
PT89802B (pt) 1994-04-29
EP0330049B1 (en) 1993-09-08
DE68908913T2 (de) 1994-01-27
IE890580L (en) 1989-08-24
DK174978B1 (da) 2004-04-05
EP0330049A3 (en) 1991-01-30
DK83889A (da) 1989-08-25
US5114916A (en) 1992-05-19
IE63656B1 (en) 1995-05-31
JPH0378850B2 (enExample) 1991-12-17
ES2059588T3 (es) 1994-11-16
KR0137476B1 (ko) 1998-06-01
DK83889D0 (da) 1989-02-23
AU3024389A (en) 1989-08-24
JPH01216939A (ja) 1989-08-30
CA1332352C (en) 1994-10-11
AU613154B2 (en) 1991-07-25
DE68908913D1 (de) 1993-10-14
KR890012659A (ko) 1989-09-18
EP0330049A2 (en) 1989-08-30

Similar Documents

Publication Publication Date Title
ATE94070T1 (de) Faktor xiii zur vorbeugung von intraventrikulaeren blutungen.
DE3872372D1 (de) Zusammensetzung zur erhoehung der intrazell-atp-spiegel und des physischen leistungsniveaus und zur erhoehung der geschwindigkeit von wundenheilung.
ATE103914T1 (de) Neue thienylcarbonsaeureester von aminoalkoholen, ihre quaternierungsprodukte sowie die herstellung und verwendung dieser verbindungen.
NO905264L (no) Fremgangsmaate for fremstilling av biologisk aktivt protein
DE3587941D1 (de) Gerät zur vorläufigen reperfusionsbehandlung von herzanfallsymptomen.
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
DE3785684D1 (de) Pyrrolidinamid-derivate von acylaminosaeure, pharmazeutische zusammensetzung und verwendung.
NO893637L (no) Fremgangsmaate for aa stabilisere blodkoagulasjonsfaktorer.
DE3880212D1 (de) Pharmazeutische zusammensetzung zur hautabsorption und hautabsorptionsverstaerkung von medikamenten.
ES2073425T3 (es) Una nueva glicoproteina de tipo trombomodulina susceptible de ser obtenida a partir de la orina.
DE3750636D1 (de) Herstellung von Titan-, Magnesium- und Zirkon-Calcium-Oxiden.
DE3869230D1 (de) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin.
DK278088D0 (da) Insulinblandindgsktystaller, deres fremstilling og anvendelse
DE69133077D1 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
ES2073391T3 (es) Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
ATE127842T1 (de) Megakaryocytopoietin, seine herstellung und benutzung.
ATE219673T1 (de) Zusammensetzung von argatroban zur verwendung in ophthalmologie
NO171912C (no) Fremgangsmaate for fremstilling av 5-klor-3-klorsulfonyl-2-tiofenkarboksylsyreestere
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
EP0214281A4 (en) Protein absorption enhancing agents.
NO890261D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydropyridin-derivater.
DK417889D0 (da) Anvendelse af 2-azabicyklo(2.2.2.)-carboxylsyrederivater til fremstilling af medicinske produkter til behandling af vaskulaere sygdomme
IT8920906A0 (it) Blocchetto di sicurezza per la prevenzione di punture accidentali con aghi di siringhe.
ATE74767T1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.
NO880831D0 (no) Rekombinant human vevsplasminogen-aktivatorblanding.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time